Related Experiment Video
Updated: Mar 24, 2026
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use
1Regis University, Denver, Colorado; Penrose-St Francis Medical Center, Colorado Springs, Colorado.
Insights
Propranolol effectively treats infantile hemangiomas, reducing lesion size and complications. Further research is needed to optimize propranolol dosage and administration for infantile hemangioma management.
Area of Science:
- Pediatric Dermatology
- Vascular Biology
Background:
- Infantile hemangiomas are common benign vascular tumors in infants.
- Their exact developmental mechanisms remain largely unknown.
- They are characterized as proliferative lesions of endothelial cells.
Purpose of the Study:
- To understand the pathogenesis of infantile hemangiomas for effective management.
- To aid healthcare providers in treatment decisions.
- To foster supportive relationships with families of affected infants.
Main Methods:
- Literature search using EBSCO host and Ovid databases.
- Keywords included: infantile hemangiomas, propranolol, vascular lesion, proliferative lesion.
- Focused on pathophysiology and recent research studies.
Main Results:
- Propranolol is a novel treatment for infantile hemangiomas.
- It demonstrates high response rates in reducing lesion size.
- It also decreases the risk of long-term complications.
Conclusions:
- Improved identification and tailored care are crucial for minimizing rare but severe complications.
- Future research should focus on optimal propranolol dosing and treatment duration.
Background:
Infantile hemangiomas are complex benign vascular tumors that present after birth. Hemangioma lesions have a predictable course of growth, but little is understood about the mechanism behind their development. Infantile hemangiomas are considered proliferative lesions of the endothelial cells.
Purpose:
To effectively manage infants with infantile hemangiomas, a clear understanding of the pathogenic pathways is important and can assist the healthcare provider with effective treatment. This understanding will facilitate a relationship of support with the families of affected infants.
Methods/Search Strategies:
EBSCO host and Ovid database search for key words of infantile hemangiomas, propranolol, vascular lesion, and proliferative lesion was utilized. Articles on pathophysiology along with recent research studies were include in the search.
Findings/Results:
The use of propranolol is a recent development in the treatment of infantile hemangiomas, which has shown a high rate of response in decreasing the size and reducing the potential for life-long complications. Different studies have shown the same success rate with the use of propranolol but with different variables.
Implications For Practice:
As a healthcare team member, better identification and customized care of these patients can reduce the rare but devastating complications of infantile hemangiomas.
Implications For Research:
Future research can help identify the most effective dose and course of propranolol administration.
More Related Videos
08:26A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
Published on: April 12, 2018
08:32Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...